-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on UroGen Pharma, Raises Price Target to $60

Benzinga·08/05/2026 20:01:16
語音播報
TD Cowen analyst Tara Bancroft maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $50 to $60.